Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

Cancer Research
Chiara CasatiChiara Castelli

Abstract

The adjuvant activities of the human lymphocyte activation gene-3 (LAG-3) molecule have been evaluated in a human setting by investigating the ability of a soluble recombinant human LAG-3 protein (hLAG-3Ig) to enhance the in vitro induction of viral- and tumor-specific CTLs. We found that soluble human LAG-3 significantly sustained the generation and expansion of influenza matrix protein Melan-A/MART-1 and survivin-specific CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMC) of both cancer patients and healthy donors, showing its ability to boost CD8+ T-cell memory response or to prime naive T cells in vitro. The peptide-specific T cells generated in the presence of hLAG-3Ig were endowed with cytotoxic activity and enhanced release of type 1 cytotoxic T (Tc1) cytokines and were able to recognize tumor cells expressing their nominal antigen. Phenotype and cytokine/chemokines produced by antigen-presenting cells (APC) of PBMCs exposed in vitro for 2 days to peptide and hLAG-3Ig indicate that the LAG-3-mediated adjuvant effect may depend on a direct activation of circulating APCs. Our data revealed the activity of hLAG-3Ig in inducing tumor-associated, antigen-specific CD8+ T-cell responses in a human setting and stron...Continue Reading

References

May 1, 1990·The Journal of Experimental Medicine·F TriebelT Hercend
Sep 8, 1999·The Journal of Experimental Medicine·T NishimuraA Ohta
Dec 22, 1999·European Journal of Immunology·P PrigentF Triebel
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S El Mir, F Triebel
Dec 19, 2001·The Journal of Experimental Medicine·T SchülerT Blankenstein
Mar 26, 2002·Nature Reviews. Immunology·Arlene H Sharpe, Gordon J Freeman
Apr 9, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Susanne AndreaeFrédéric Triebel
Jun 6, 2002·Journal of the National Cancer Institute·Giorgio ParmianiAndrea Anichini
Jul 13, 2002·European Journal of Immunology·Christian LienhardtGianfranco Del Prete
Nov 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Creg J WorkmanDario A A Vignali
Nov 26, 2002·Immunological Reviews·Licia RivoltiniGiorgio Parmiani
Dec 24, 2002·Trends in Immunology·Gilles KaplanskiCatherine Farnarier
Jan 18, 2003·Science·Chandrashekhar Pasare, Ruslan Medzhitov
Oct 14, 2003·Drug Discovery Today·Dante J Marciani
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yong ZhengDavid M Sansom
Oct 16, 2004·Immunity·Ching-Tai HuangDario A A Vignali
Dec 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fabio Re, Jack L Strominger
Feb 25, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul A AntonyNicholas P Restifo
May 12, 2005·Immunology·Laëtitia Maçon-Lemaître, Frédéric Triebel
May 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Junichi EguchiHideho Okada
Jun 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Rachel M McLoughlinSimon A Jones
Jul 8, 2005·Journal of Immunotherapy·Jan Muller-BerghausWalter J Storkus

❮ Previous
Next ❯

Citations

Nov 11, 2008·Cancer Immunology, Immunotherapy : CII·Manuela IeroLicia Rivoltini
Dec 22, 1999·Trends in Microbiology·F García-Del Portillo
Aug 23, 2006·Nature Immunology·Sawsan Youssef, Lawrence Steinman
Aug 29, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Escudier
Sep 12, 2015·Acta Oncologica·Xiaodong LiChangping Wu
Dec 15, 2010·Expert Opinion on Therapeutic Targets·Sophie SierroDaniel E Speiser
Oct 23, 2012·European Urology·Brant A InmanDaniel J George
Jan 21, 2014·The Journal of Investigative Dermatology·Chiara CamisaschiChiara Castelli
Nov 19, 2015·Molecular Oncology·Anna ŚledzińskaSergio A Quezada
May 12, 2009·Immunological Reviews·Gregory DriessensThomas F Gajewski
Jan 15, 2015·Cancer Treatment Reviews·F MassariG Tortora
Dec 24, 2014·Nature Reviews. Immunology·Linh T Nguyen, Pamela S Ohashi
Jun 15, 2016·Cancer Science·Yayi HeFred R Hirsch
Jun 5, 2007·Expert Review of Vaccines·Clint S SchmidtNadeem A Sheikh
Mar 29, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrice HemonLaurence Michel
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chiara CasatiChiara Castelli
May 10, 2018·Hepatology International·Antonio Riva, Shilpa Chokshi
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chrystelle BrignoneFrédéric Triebel
Sep 15, 2018·Therapeutic Advances in Respiratory Disease·Nicolas Villanueva, Lyudmila Bazhenova
Oct 30, 2020·Biotechnology Progress·Saeed Mohammadian HaftcheshmehMahmoud Reza Jaafari
Apr 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew KramanNeil Brewis
Mar 3, 2021·Current Rheumatology Reports·Stinne Ravn Greisen, Bent Deleuran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.